Low/Intermediate PCa video chat, Sep 23, 2024

by | Sep 24, 2024 | Active Surveillance PCa, Cancer Resources, High Risk/Recurrent/Advanced Prostate Cancer, Low/Intermediate Prostate Cancer, Recorded Groups

Low/Intermediate PCa

Low/Intermediate PCa Video Chat, Sep 23, 2024

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.

WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.

Join our other free and drop in groups:
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!

Editor’s Pick: RTIRE trial — a patient perspective (bj)

Topics Discussed

Tulsa Procedure (Tulsa Pro) questions; patient experience with RTIRE trial; types of biopsies (transrectal and transperineal); ArteraAI prostate cancer test; radiation treatment considerations when urinary conditions exist; when do I belong in AnCan’s High Risk/Recurrent/Advance Group?; interpreting prostatic capsular abutment as a risk factor; positive feedback from the 2024 PRCI Men’s Health Conference attendees; AnCan Low/Intermediate Group success stories.

Chat Log

Boykin Jordan (DC Metro)
What is the name of the trial that Stuart is referring to?

AnCan – rick
electroporation + IMRT, Boykin. Let me see if I can find name

Dennis S
Thank you. I was hoping to respond to the previous speaker

AnCan – rick
RTIRE – https://pubmed.ncbi.nlm.nih.gov/39054460/

Jim Stewart   Reno, NV
good night all…grandkid duty calls!!!